These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 12507764)
1. Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. Charrois GJ; Allen TM Biochim Biophys Acta; 2003 Jan; 1609(1):102-8. PubMed ID: 12507764 [TBL] [Abstract][Full Text] [Related]
2. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Charrois GJ; Allen TM Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619 [TBL] [Abstract][Full Text] [Related]
3. Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity. Charrois GJ; Allen TM J Pharmacol Exp Ther; 2003 Sep; 306(3):1058-67. PubMed ID: 12808004 [TBL] [Abstract][Full Text] [Related]
4. From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Cattel L; Ceruti M; Dosio F Tumori; 2003; 89(3):237-49. PubMed ID: 12908776 [TBL] [Abstract][Full Text] [Related]
5. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity. Nishida K; Kashiwagi M; Shiba S; Muroki K; Ohishi A; Doi Y; Ando H; Ishida T; Nagasawa K Toxicol Appl Pharmacol; 2017 Dec; 337():76-84. PubMed ID: 29054682 [TBL] [Abstract][Full Text] [Related]
6. Assessment of liposome biodistribution by non-invasive optical imaging: a feasibility study in tumour-bearing mice. Hagtvet E; Evjen TJ; Nilssen EA; Olsen DR J Nanosci Nanotechnol; 2012 Mar; 12(3):2912-8. PubMed ID: 22755141 [TBL] [Abstract][Full Text] [Related]
7. Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx Burade V; Bhowmick S; Maiti K; Zalawadia R; Jain D; Rajamannar T Cancer Chemother Pharmacol; 2017 May; 79(5):899-913. PubMed ID: 28349166 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395 [TBL] [Abstract][Full Text] [Related]
9. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Liu D; Mori A; Huang L Biochim Biophys Acta; 1992 Feb; 1104(1):95-101. PubMed ID: 1550858 [TBL] [Abstract][Full Text] [Related]
10. Targeting Stealth liposomes in a murine model of human small cell lung cancer. Moreira JN; Gaspar R; Allen TM Biochim Biophys Acta; 2001 Dec; 1515(2):167-76. PubMed ID: 11718672 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products? Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737 [TBL] [Abstract][Full Text] [Related]
12. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Gabizon A; Shmeeda H; Barenholz Y Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Huang SK; Mayhew E; Gilani S; Lasic DD; Martin FJ; Papahadjopoulos D Cancer Res; 1992 Dec; 52(24):6774-81. PubMed ID: 1458465 [TBL] [Abstract][Full Text] [Related]
15. From conventional to stealth liposomes: a new Frontier in cancer chemotherapy. Cattel L; Ceruti M; Dosio F J Chemother; 2004 Nov; 16 Suppl 4():94-7. PubMed ID: 15688621 [TBL] [Abstract][Full Text] [Related]
16. Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity. Shmeeda H; Amitay Y; Tzemach D; Gorin J; Gabizon A J Control Release; 2013 May; 167(3):265-75. PubMed ID: 23419948 [TBL] [Abstract][Full Text] [Related]
17. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes. Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877 [TBL] [Abstract][Full Text] [Related]
18. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine. Allen TM; Mehra T; Hansen C; Chin YC Cancer Res; 1992 May; 52(9):2431-9. PubMed ID: 1568213 [TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Newman MS; Colbern GT; Working PK; Engbers C; Amantea MA Cancer Chemother Pharmacol; 1999; 43(1):1-7. PubMed ID: 9923534 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Allen TM; Hansen C Biochim Biophys Acta; 1991 Sep; 1068(2):133-41. PubMed ID: 1911826 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]